SCHEMBL62408

SCHEMBL62408

Cc1nccn1-c1cccc(N)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.57
CYP2E1 P05181 1/20 0.57
CYP2A6 P11509 1/20 0.57
MAPT P10636 2/20 0.49
ALDH1A1 P00352 2/20 0.49
KDM4E B2RXH2 1/20 0.49
MEN1 O00255 1/20 0.49
ALOX15 P16050 1/20 0.49
CASP1 P29466 1/20 0.49
CASP7 P55210 1/20 0.49
KMT2A Q03164 1/20 0.49
MAOA P21397 1/20 0.45
MAOB P27338 1/20 0.45
GRM5 P41594 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP19A1 P11511 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
ICMT O60725 3/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11929770 0.87 CYP3A4 (0.67) CYP3A4CYP2E1CYP2A6ALDH1A1MAOA
SCHEMBL17166601 0.82 CYP3A4 (0.61) CYP3A4CYP2E1CYP2A6ALDH1A1MAOA
SCHEMBL6262265 0.82 MAPT (0.50) CYP3A4CYP2E1CYP2A6MAPTALDH1A1
SCHEMBL28354375 0.80 KDR (0.54) MAPTALDH1A1KDM4EMEN1ALOX15
SCHEMBL16923147 0.79 CYP3A4 (0.57) CYP3A4CYP2E1CYP2A6ALDH1A1MAOA
SCHEMBL22290749 0.79 CYP3A4 (0.57) CYP3A4CYP2E1CYP2A6ALDH1A1MEN1
SCHEMBL3507152 0.79 CYP3A4 (0.57) CYP3A4CYP2E1CYP2A6ALDH1A1MAOA
SCHEMBL11983591 0.79 CYP3A4 (0.57) CYP3A4CYP2E1CYP2A6ALDH1A1MAOA
SCHEMBL30797803 0.79 CYP3A4 (0.57) CYP3A4CYP2E1CYP2A6ALDH1A1MAOA
SCHEMBL10641492 0.79 MAPT (0.47) CYP3A4MAPTALDH1A1KDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110776657-B High-thermal-conductivity polyimide film and preparation method thereof 株洲时代华鑫新材料技术有限公司 2022-02-11 CN claimed
CN-110776657-A High-thermal-conductivity polyimide film and preparation method thereof 株洲时代新材料科技股份有限公司 2020-02-11 CN claimed
US-4533669-A NONTOXIC EISAI CO., LTD. (JP) 1985-08-06 US claimed
US-20240216355-A1 PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS MONTE ROSA THERAPEUTICS AG (CH) 2024-07-04 US disclosed
EP-4313047-A1 PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS Monte Rosa Therapeutics, Inc. (US) 2024-02-07 EP disclosed
WO-2022200857-A1 PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS MONTE ROSA THERAPEUTICS AG (CH) 2022-09-29 WO disclosed
EP-4041231-A1 ISOINDOLINONE COMPOUNDS Monte Rosa Therapeutics AG (CH) 2022-08-17 EP disclosed
US-20220242846-A1 ISOINDOLINONE COMPOUNDS MONTE ROSA THERAPEUTICS AG (CH) 2022-08-04 US disclosed
CN-110776657-B High-thermal-conductivity polyimide film and preparation method thereof 株洲时代华鑫新材料技术有限公司 2022-02-11 CN disclosed
WO-2021069705-A1 ISOINDOLINONE COMPOUNDS MONTE ROSA THERAPEUTICS (CH) 2021-04-15 WO disclosed
WO-2021069705-A1 ISOINDOLINONE COMPOUNDS MONTE ROSA THERAPEUTICS (CH) 2021-04-15 WO disclosed
EP-0821684-A1 BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS MODULATORS OF THE GABA A? RECEPTOR COMPLEX NEUROSEARCH A/S (DK) 1998-02-04 EP disclosed
WO-1996033194-A1 BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS MODULATORS OF THE GABA A RECEPTOR COMPLEX NEUROSEARCH A/S (DK) 1996-10-24 WO disclosed
US-5231182-A Platelet activating factor inhibitor AMERICAN CYANAMID COMPANY (US) 1993-07-27 US disclosed
US-5189055-A Antimitotic, anticarcinogenic CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 1993-02-23 US disclosed
US-5077409-A Reducing hydroxy bis-aryl amide, acylating, hydrolyzing, sulfonating, halogenating, alkylating with nitrogen heterocycle AMERICAN CYANAMID COMPANY (US) 1991-12-31 US disclosed
US-4602031-A Anti-depressant imidazoles, compositions and use EISAI CO., LTD. (JP) 1986-07-22 US disclosed
US-4533669-A NONTOXIC EISAI CO., LTD. (JP) 1985-08-06 US disclosed
US-4402966-A Acylaminophenyl imidazoles and anti-depressing agent containing the same EISAI CO., LTD. (JP) 1983-09-06 US disclosed
US-4301169-A Novel imidazole compound and anti-depressing agent containing the same EISAI CO., LTD. (JP) 1981-11-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240216355-A1 PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS UPF1, NSUN2, RTF2 CYP3A4 3128/4885CYP2E1 2728/4885CYP2A6 735/4885
US-20220242846-A1 ISOINDOLINONE COMPOUNDS AOC2, AOC3, INF2 CYP3A4 463/4885CYP2E1 223/4885CYP2A6 141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.